Clinical Study

Bioartificial Therapy of Sepsis: Changes of Norepinephrine-Dosage in Patients and Influence on Dynamic and Cell Based Liver Tests during Extracorporeal Treatments

Figure 5

Activity of cytochrome 1A2 (metabolism of ethoxyresorufin to resorufin) and the XTT-test (dehydrogenases activity in the mitochondria) of HepG2/C3A cells (biosensor-test) incubated with plasma from septic patients before extracorporeal treatments compared to plasma from patients after extracorporeal granulocyte treatments (Mann-Whitney U test; ; median/0.25–0.75 quartile). .